Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization

The incidence of antiplatelet factor-4/heparin antibody formation in patients who receive contemporary doses of unfractionated heparin in the setting of percutaneous coronary revascularization is unknown. Also unknown is the ability of these antibodies to activate platelets or adversely affect clini...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of cardiology 2005-03, Vol.95 (6), p.744-747
Hauptverfasser: Gluckman, Tyler J., Segal, Jodi B., Fredde, Natalie L., Saland, Kenneth E., Jani, Jayesh T., Walenga, Jeanine M., Prechel, M. Margaret, Citro, Kathleen M., Zidar, David A., Fox, Emily, Schulman, Steven P., Kickler, Thomas S., Rade, Jeffrey J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The incidence of antiplatelet factor-4/heparin antibody formation in patients who receive contemporary doses of unfractionated heparin in the setting of percutaneous coronary revascularization is unknown. Also unknown is the ability of these antibodies to activate platelets or adversely affect clinical outcome in the absence of clinically recognized heparin-induced thrombocytopenia. To address these questions, we serially measured antiplatelet factor-4/heparin antibody levels and performed serotonin release assays in patients who underwent percutaneous coronary intervention. Correlations were then made across antibody induction, heparin exposure, and clinical outcome at 6 months.
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2004.11.026